| 
						
						
						 Uganda 
						clears three experimental Ebola treatments, watches for 
						spread
   Send a link to a friend 
		[June 18, 2019]  
		By Elias Biryabarema
 KAMPALA (Reuters) - Health workers have got 
		the all-clear to use three experimental Ebola treatments in Uganda, a 
		week after the deadly disease spread over the border from Democratic 
		Republic of Congo, authorities said on Tuesday.
 | 
        
            | 
			
			 Two people who had traveled from Congo died in Uganda last week, the 
			World Health Organization said. A three-year-old boy who was sent 
			back to Congo after testing positive for the disease died at the 
			weekend, Congo's health ministry said. 
 At least another 1,411 people have died in Congo since August in the 
			second worst outbreak of the disease on record.
 
 "Happy to inform you all that we got clearance from both Uganda 
			National Council for Science and Technology and National Drug 
			Authority to bring in the Therapeutic treatment for #Ebola patients 
			in the country," Uganda's Health Minister, Jane Ruth Aceng, said on 
			Twitter.
 
			
			 
			The treatments approved for shipment to Uganda were Mapp 
			Biopharmaceutical's ZMapp, Regeneron Pharmaceuticals Inc's Regeneron 
			and Remdesivir, made by Gilead Sciences, said WHO spokesman Tarik 
			Jasarevic.
 “The protocols for the fourth being submitted. Logistics underway 
			with MSF support for importation of a few courses about 10 each,” he 
			added in an email.
 
 The U.N. health agency has said there have so far been no known 
			cases of Ebola spreading between people in Uganda - all recorded 
			patients had traveled in from Congo.
 
			
            [to top of second column] | 
            
			 
			Four experimental therapeutic treatments are already being used in 
			Congo, it added.
 On Friday, a WHO panel decided not to declare an international 
			emergency over Congo's Ebola outbreak despite its spread to Uganda, 
			saying such a declaration could cause too much economic harm.
 
 "Obviously, the crisis is far from over," Mark Green, the head of 
			the U.S. Agency for International Development (USAID), told a news 
			conference in Nairobi.
 
 Health workers and people who came in contact with infected people 
			began receiving a Merck experimental vaccine in Uganda on Saturday.
 
 (Additional reporting by Tom Miles and Stephanie Nebehay in Geneva, 
			Omar Mohammed in Nairobi and Kate Kelland in London; Writing by 
			George Obulutsa)
 
			[© 2019 Thomson Reuters. All rights 
				reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content. 
			
			
			 |